KaliVir Immunotherapeutics Closes Series A Financing

March 16, 2022

Download the press release (PDF)

All news releases

This site contains information about VET3-TGI, an investigational agent that has not been reviewed or approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy have not been established.

KaliVir Immunotherapeutics, Inc.
240 Alpha Drive
Pittsburgh, PA 15238
412-435-6730

Research & Innovation

Our Science
VET™ Platform
Discovery Research
Pipeline
STEALTH-001 Study
Publications
Presentations

Our Science
VET™ Platform
Discovery Research
Pipeline
STEALTH-001 Study
Publications
Presentations

Company

About Us
Leadership
Board of Directors
Advisory Boards
Partnering
Careers

About Us
Leadership
Board of Directors
Advisory Boards
Partnering
Careers

Resources

News
Contact

News
Contact

Forward-looking statements

This website contains forward-looking statements within the meaning of applicable U.S. securities laws. These statements involve risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied. All statements other than statements of historical fact may be forward-looking, including statements about our plans, strategies and objectives for clinical development, manufacturing and commercialization; our product pipeline and clinical data and their implications; the enforceability of our intellectual property; our competitive position; and the anticipated benefits of our collaborations and partnerships. Information on this website is provided in summary form, speaks only as of the date it was posted, and KaliVir undertakes no obligation to update it except as required by law.

Privacy Policy
Terms of Use
Cookie Policy

Privacy Policy
Terms of Use
Cookie Policy